{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cytokine+Release+Syndrome&page=3",
    "query": {
      "condition": "Cytokine Release Syndrome",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 63,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cytokine+Release+Syndrome&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cytokine+Release+Syndrome&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-03T03:20:14.202Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04869579",
      "title": "Selenium as a Potential Treatment for Moderately-ill, Severely-ill, and Critically-ill COVID-19 Patients.",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "Selenium (as Selenious Acid)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "CHRISTUS Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2021-08-15",
      "completion_date": "2021-12-15",
      "has_results": false,
      "last_update_posted_date": "2021-08-03",
      "last_synced_at": "2026-10-03T03:20:14.202Z",
      "location_count": 1,
      "location_summary": "Longview, Texas",
      "locations": [
        {
          "city": "Longview",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04869579"
    },
    {
      "nct_id": "NCT04377620",
      "title": "Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 211,
      "start_date": "2020-05-24",
      "completion_date": "2021-02-26",
      "has_results": true,
      "last_update_posted_date": "2022-01-19",
      "last_synced_at": "2026-10-03T03:20:14.202Z",
      "location_count": 35,
      "location_summary": "Scottsdale, Arizona • San Diego, California • Washington D.C., District of Columbia + 29 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Brandon",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04377620"
    },
    {
      "nct_id": "NCT07567014",
      "title": "Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma",
        "Large B-cell Lymphoma (LBCL)"
      ],
      "interventions": [
        {
          "name": "Emapalumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2026-05-11",
      "completion_date": "2029-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-10-03T03:20:14.202Z",
      "location_count": 3,
      "location_summary": "Brooklyn, New York • Manhattan, New York • Mineola, New York",
      "locations": [
        {
          "city": "Brooklyn",
          "state": "New York"
        },
        {
          "city": "Manhattan",
          "state": "New York"
        },
        {
          "city": "Mineola",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07567014"
    },
    {
      "nct_id": "NCT04362137",
      "title": "Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cytokine Storm (Covid-19)"
      ],
      "interventions": [
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 432,
      "start_date": "2020-05-02",
      "completion_date": "2020-10-17",
      "has_results": true,
      "last_update_posted_date": "2021-10-11",
      "last_synced_at": "2026-10-03T03:20:14.202Z",
      "location_count": 11,
      "location_summary": "Fullerton, California • Aurora, Colorado • Denver, Colorado + 8 more",
      "locations": [
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Idaho Falls",
          "state": "Idaho"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04362137"
    },
    {
      "nct_id": "NCT06415656",
      "title": "VitalTraq for the Detection of CRS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hematologic Malignancy"
      ],
      "interventions": [
        {
          "name": "TempTraq",
          "type": "DEVICE"
        },
        {
          "name": "VitalTraq",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2024-10-13",
      "completion_date": "2025-07-07",
      "has_results": true,
      "last_update_posted_date": "2026-07-15",
      "last_synced_at": "2026-10-03T03:20:14.202Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06415656"
    },
    {
      "nct_id": "NCT07609940",
      "title": "Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Relapsed/Refractory Multiple Myeloma (RRMM)"
      ],
      "interventions": [
        {
          "name": "Linvoseltamab",
          "type": "DRUG"
        },
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2026-07-15",
      "completion_date": "2028-12-06",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-10-03T03:20:14.202Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • St. Petersburg, Florida • Baton Rouge, Louisiana + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Tacoma",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07609940"
    },
    {
      "nct_id": "NCT04351152",
      "title": "Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Coronavirus Disease 2019 (COVID-19) Pneumonia"
      ],
      "interventions": [
        {
          "name": "Lenzilumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard of Care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Humanigen, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 520,
      "start_date": "2020-05-05",
      "completion_date": "2021-03",
      "has_results": false,
      "last_update_posted_date": "2021-03-03",
      "last_synced_at": "2026-10-03T03:20:14.202Z",
      "location_count": 18,
      "location_summary": "Phoenix, Arizona • Irvine, California • Los Angeles, California + 13 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04351152"
    },
    {
      "nct_id": "NCT04975555",
      "title": "Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cytokine Release Syndrome",
        "ICANS",
        "Lymphoma, Non-Hodgkin",
        "Multiple Myeloma",
        "Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "Siltuximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2021-11-15",
      "completion_date": "2026-01-20",
      "has_results": true,
      "last_update_posted_date": "2026-07-27",
      "last_synced_at": "2026-10-03T03:20:14.202Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04975555"
    },
    {
      "nct_id": "NCT04071366",
      "title": "A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cytokine Release Syndrome"
      ],
      "interventions": [
        {
          "name": "Itacitinib",
          "type": "DRUG"
        },
        {
          "name": "Immune effector cell therapy",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Yescarta",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 112,
      "start_date": "2020-02-07",
      "completion_date": "2023-08-22",
      "has_results": true,
      "last_update_posted_date": "2024-03-26",
      "last_synced_at": "2026-10-03T03:20:14.202Z",
      "location_count": 10,
      "location_summary": "Miami, Florida • Tampa, Florida • Boston, Massachusetts + 6 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04071366"
    },
    {
      "nct_id": "NCT04415073",
      "title": "A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Coronavirus",
        "COVID",
        "ARDS",
        "Cytokine Storm",
        "Cytokine Release Syndrome"
      ],
      "interventions": [
        {
          "name": "SNDX-6352",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Syndax Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2020-05-30",
      "completion_date": "2020-07-13",
      "has_results": true,
      "last_update_posted_date": "2022-07-22",
      "last_synced_at": "2026-10-03T03:20:14.202Z",
      "location_count": 2,
      "location_summary": "Scottsdale, Arizona • The Bronx, New York",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04415073"
    }
  ]
}